Japan’s Kowa says ivermectin showed ‘antiviral effect’ against omicron in research

Published: Updated:
Enable Read mode
100% Font Size

Japanese trading and pharmaceutical company Kowa Co Ltd said on Monday anti-parasite drug ivermectin showed an “antiviral effect” against omicron and other variants of coronavirus in joint non-clinical research.

For more coronavirus news, visit our dedicated page.

Kowa did not provide further details. The firm has been working with Kitasato University, a medical university in Tokyo.


Clinical trials evaluating the drug, which is used to treat parasites in animals and humans, are ongoing but promotion of the drug as a COVID-19 treatment has generated controversy

The drug is not approved for treatment of COVID-19 in Japan and the US Federal Drug Administration has repeatedly warned against its use.

Read more:

Russia sees over 100,000 daily COVID-19 cases for first time

Canada truckers head for Ottawa to protest vaccine mandate

COVID-19 cases plateauing in parts of India but omicron still surges

Top Content Trending